Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DM 101

Next Previous
X
Search
Drug Profile

DM 101

Alternative Names: AllergyVax; Be-v-1-dm; Bet v 1 dm; DM 101PX; DM-101; rBet-v-1-dm

Latest Information Update: 04 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Desentum; University of Eastern Finland; VTT Technical Research Centre of Finland
  • Developer Desentum
  • Class Allergens; Tree pollen allergy immunotherapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Tree pollen hypersensitivity

Most Recent Events

  • 06 Mar 2024 Desentum completes a phase I trial in Tree pollen hypersensitivity in Canada (SC) (NCT06037148)
  • 07 Sep 2023 Phase-I clinical trials in Tree pollen hypersensitivity in Canada (SC) (NCT06037148)
  • 28 Mar 2023 No recent reports of development identified for phase-I development in Tree pollen hypersensitivity in Finland (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top